Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals Q2 2025 Earnings Report

Enanta Pharmaceuticals logo
$5.97 -0.19 (-3.08%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$5.93 -0.04 (-0.67%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals EPS Results

Actual EPS
-$1.06
Consensus EPS
-$1.04
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Enanta Pharmaceuticals Revenue Results

Actual Revenue
$14.93 million
Expected Revenue
$15.96 million
Beat/Miss
Missed by -$1.04 million
YoY Revenue Growth
N/A

Enanta Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
12:30PM ET

Upcoming Earnings

Enanta Pharmaceuticals' Q3 2025 earnings is scheduled for Monday, August 11, 2025, with a conference call scheduled on Monday, August 4, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Enanta Pharmaceuticals Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA), a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

View Enanta Pharmaceuticals Profile

More Earnings Resources from MarketBeat